These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17785973)

  • 1. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
    Langgartner J; Lehn N; Glück T; Herzig H; Kees F
    Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
    Newman D; Scheetz MH; Adeyemi OA; Montevecchi M; Nicolau DP; Noskin GA; Postelnick MJ
    Ann Pharmacother; 2007 Oct; 41(10):1734-9. PubMed ID: 17726066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily serum piperacillin monitoring is advisable in critically ill patients.
    Blondiaux N; Wallet F; Favory R; Onimus T; Nseir S; Courcol RJ; Durocher A; Roussel-Delvallez M
    Int J Antimicrob Agents; 2010 May; 35(5):500-3. PubMed ID: 20226635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of piperacillin during continuous ambulatory peritoneal dialysis].
    Ryckelynck JP; Debruyne D; Hurault De Ligny B; Moulin M
    Pathol Biol (Paris); 1988 May; 36(5):507-10. PubMed ID: 3043348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data.
    Hung MN; Hsueh PR; Chang HT; Lee WS; Chou MY; Chen IS; Wang JH; Lin CF; Shyr JM; Ko WC; Wu JJ; Liu YC; Huang WK; Teng LJ; Liu CY; Luh KT
    Int J Antimicrob Agents; 2007 Feb; 29(2):145-52. PubMed ID: 16815690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.
    Breilh D; Fleureau C; Gordien JB; Joanes-Boyau O; Texier-Maugein J; Rapaport S; Boselli E; Janvier G; Saux MC
    Minerva Anestesiol; 2011 Nov; 77(11):1058-62. PubMed ID: 21597443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model.
    Bantar C; Canigia LF; Berger MA; Soutric JL; Arenoso HJ
    Braz J Infect Dis; 2009 Oct; 13(5):348-52. PubMed ID: 20428633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.